Crinetics to Present Long-Term Paltusotine Data and Atumelnant Phase 2 Results at ENDO 2026
核心洞察
Crinetics Pharmaceuticals will present six datasets at ENDO 2026, including long-term safety and efficacy from the PATHFNDR open-label extension studies for paltusotine.
Three presentations will focus on the atumelnant clinical program, featuring Phase 2 data in congenital adrenal hyperplasia (搜索) and Phase 1b/2a results in ACTH-dependent Cushing's syndrome (搜索).
All eight covering analysts maintain Buy ratings on CRNX with a consensus 1-year target price of $88.14, representing over 167% upside potential.
Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is set to deliver six presentations at the Endocrine Society's Annual Meeting, ENDO 2026, in mid-June, the company announced on June 2. The presentations will span two core clinical programs — paltusotine and atumelnant — and will feature long-term extension data alongside mid-stage results in rare endocrine conditions.
The meeting marks a significant data disclosure moment for the San Diego-based biotech, which focuses exclusively on rare endocrine diseases and endocrine-related tumors.
Paltusotine Long-Term Data in Focus
Three of the six presentations will center on PALSONIFY, the brand name associated with paltusotine, and will incorporate long-term safety and efficacy data drawn from the open-label extension (OLE) studies known as PATHFNDR-1 and PATHFNDR-2. These extension studies provide critical durability evidence for paltusotine, an investigational therapy designed to address unmet needs in specific endocrine disorders.
The PATHFNDR program has been closely watched by analysts and clinicians alike, as it underpins the regulatory and commercial thesis for paltusotine. The ENDO 2026 presentations are expected to shed light on how patients fare over extended treatment periods, a key consideration for chronic endocrine conditions requiring lifelong management.
Atumelnant Advances Across Two Indications
The remaining three presentations will highlight the atumelnant clinical development program. Crinetics will share data from a Phase 2 study evaluating atumelnant in congenital adrenal hyperplasia (搜索) (CAH), a rare genetic disorder affecting the adrenal glands. Additionally, the company will present Phase 1b/2a results for atumelnant in ACTH-dependent Cushing's syndrome (搜索), a condition characterized by excess cortisol production driven by adrenocorticotropic hormone.
Atumelnant represents a cornerstone of Crinetics' broader pipeline, which also includes CRN09682 and oral nonpeptide GLP-1 and GIP programs — all targeting various aspects of endocrine dysfunction.
Analyst Sentiment Remains Strongly Bullish
As of the June 5 close, Crinetics Pharmaceuticals carried a strongly bullish consensus sentiment among Wall Street analysts. All eight analysts providing coverage have issued Buy ratings on the stock. The consensus 1-year target price stands at $88.14, implying an upside potential exceeding 167% from prevailing levels.
On May 15, Evercore ISI analyst Gavin Clark-Gartner modestly adjusted his price target from $89 to $88 while maintaining an Outperform rating, reflecting continued confidence in the company's trajectory ahead of the ENDO 2026 data presentations.
Crinetics' focused pipeline strategy in rare endocrine diseases, combined with the upcoming clinical data disclosures, positions the company at a potentially pivotal juncture as it advances multiple programs toward later-stage development.